Oakes, David, 1947-
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
David Oakes British-American medical statistician
Oakes, D.
Oakes, David (Statistician)
Oakes, D. 1947-....
Oakes, David, Ph. D.
VIAF ID: 59160127 (Personal)
Permalink: http://viaf.org/viaf/59160127
Preferred Forms
-
100 0 _
‡a
David Oakes
‡c
British-American medical statistician
-
200 _ |
‡a
Oakes
‡b
D.
‡f
1947-....
-
200 _ 1 ‡a Oakes ‡b David ‡f 1947-
-
100 1 _ ‡a Oakes, D.
-
100 1 _ ‡a Oakes, D.
-
100 1 _
‡a
Oakes, D.
(sparse)
-
100 1 _
‡a
Oakes, David
‡c
(Statistician)
-
100 1 _ ‡a Oakes, David ‡d (1947- ).
-
100 1 _
‡a
Oakes, David
‡d
1947-
-
100 1 _
‡a
Oakes, David
‡d
1947-
-
100 1 _
‡a
Oakes, David
‡d
1947-
-
100 1 _ ‡a Oakes, David, ‡c Ph. D.
-
100 1 _
‡a
Oakes, David,
‡d
1947-....
-
100 1 _ ‡a Oakes, David, ‡d 1947-
-
100 1 _ ‡a Oakes, David, ‡d 1947-
4xx's: Alternate Name Forms (15)
5xx's: Related Names (1)
Works
| Title | Sources |
|---|---|
| [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression |
|
| Analiz dannych tipa vremeni žizni |
|
| Analysis of survival data, 1984: |
|
| Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease |
|
| Cardiovascular effects of ozone in healthy subjects with and without deletion of glutathione-S-transferase M1 |
|
| Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. |
|
| The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study |
|
| Clinical and Imaging Progression in the PARS Cohort: Long-Term Follow-up |
|
| Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial |
|
| Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings |
|
| Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort |
|
| A course in the large sample theory of statistical inference |
|
| The CREST-E study of creatine for Huntington disease: A randomized controlled trial |
|
| Crossing boundaries / John E. Kolassa and David Oakes, editors. - Beachwood, Ohio, cop. 2003. |
|
| Crossing boundaries : statistical essays in honor of Jack Hall |
|
| Design and analysis of two-period studies of potentially disease-modifying treatments. |
|
| Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD) |
|
| Detection of a group of risk factors in coronary disease using a new carriership analysis approach |
|
| Detection of Huntington's disease decades before diagnosis: the Predict-HD study |
|
| Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants |
|
| Does total antioxidant capacity modify adverse cardiac responses associated with ambient ultrafine, accumulation mode, and fine particles in patients undergoing cardiac rehabilitation? |
|
| Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease |
|
| Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments |
|
| Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction |
|
| Effects of outdoor air pollutants on platelet activation in people with type 2 diabetes. |
|
| Fatigue in levodopa-naive subjects with Parkinson disease |
|
| Fear of health insurance loss among individuals at risk for Huntington disease |
|
| Head injury and Parkinson's disease risk in twins |
|
| Health monitoring scheme for firemen, 1980: |
|
| High-dosage vitamin E supplementation and all-cause mortality |
|
| HTRF analysis of soluble huntingtin in PHAROS PBMCs |
|
| Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial |
|
| Impact of sustained deprenyl |
|
| Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. |
|
| Improving clinical practice guidelines for practicing cardiologists. |
|
| Inaugural Huntington Disease Clinical Research Symposium Organized by the Huntington Study Group. |
|
| Informativeness of Early Huntington Disease Signs about Gene Status. |
|
| Inhalation of ultrafine carbon particles alters heart rate and heart rate variability in people with type 2 diabetes |
|
| Interrater agreement in the assessment of motor manifestations of Huntington's disease |
|
| Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease |
|
| Long-term palliation with the classic Blalock-Taussig shunt. |
|
| Longitudinal follow-up of SWEDD subjects in the PRECEPT Study |
|
| Measuring the effects of therapy in Parkinson disease |
|
| Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments |
|
| The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group. |
|
| Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology |
|
| Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial |
|
| Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study |
|
| Preparing for preventive clinical trials: the Predict-HD study |
|
| Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients |
|
| The prognostic significance of first myocardial infarction type (Q wave versus non-Q wave) and Q wave location. The Multicenter Diltiazem Post-Infarction Research Group |
|
| The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation |
|
| Randomized clinical trial of pacifier use and bottle-feeding or cupfeeding and their effect on breastfeeding |
|
| Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial |
|
| Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms |
|
| Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease |
|
| Reply: Unusual DAT scan results |
|
| Reproducibility of data-driven Parkinson's disease subtypes for clinical research |
|
| Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea |
|
| Safety of rasagiline in elderly patients with Parkinson disease |
|
| Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease |
|
| Senior academic physicians and retirement considerations |
|
| Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. |
|
| Statistical modeling for biological systems in memory of Andrei Yakovlev |
|
| The tampon test for vulvodynia treatment outcomes research: reliability, construct validity, and responsiveness. |
|
| Thrombogenic factors and recurrent coronary events |
|
| Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease |
|
| Urate as a predictor of the rate of clinical decline in Parkinson disease |
|
| Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study |
|
| Verbal episodic memory declines prior to diagnosis in Huntington's disease |
|
